Skip to main content

IMS Events Main banner

Myeloma Novel Drug Targets and agents

Myeloma Novel Drug Targets and agents

Type here to filter the list

(PA-282) Pan-RAS Inhibitor RMC-6236 Suppresses Myeloma Growth and Shows Enhanced Efficacy with SWI/SNF Inhibition
(PA-283) Fueling the Fighters: Cytokine-Driven Optimization of Allogeneic NK Cells for Multiple Myeloma Immunotherapy
(PA-284) Quadruplet Therapy and ASCT in Multiple Myeloma: Does It Increase Toxicity?
(PA-285) Secondary Clones Identified by Mass Spectrometry in Baseline Samples Remain Stable or Disappear Early During Monitoring in Multiple Myeloma Patients
(PA-287) A New Pikfyve Inhibitor Shows Subnanomolar Potency in Multiple Myeloma
(PA-288) Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1
(PA-289) Enhanced Expression of TAGLN2 Predicts Negative Prognosis in Multiple Myeloma
(PA-290) Optimal Treatment Strategy of Bisphosphonate Therapy in Multiple Myeloma: A Target Trial Emulation Study of Fracture Prevention versus Osteonecrosis of the Jaw Risk Using Nationwide Data
(PA-291) Comparative Analysis of Motixafortide versus Plerixafor for Stem Cell Mobilization and Collection in Multiple Myeloma: A Single Center Real-world Experience
(PA-292) Development of Novel CREB1-PROTACs for Enhanced Targeting of CREB1 in Multiple Myeloma
(PA-293) Anti-adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma
(PA-294) Safety Profile and Toxicity Comparison of Bispecific Antibodies in Relapse Refractory Multiple Myeloma: A Systematic Review of Clinical Trials
(PA-295) Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
(PA-296) Treatment Patterns and Outcomes in the Second and Third Lines and After Triple-class Exposure: Subanalysis of the Latin American Multiple Myeloma Registry Study (MYLACRE)
(PA-297) Functional Evaluation of RHEB as a Lineage-Selective Dependency in Multiple Myeloma Using Integrated CRISPR, Epigenetic, and Expression Analyses
(PA-298) Uncovering Shared Cancer-restricted Cryptic Antigens as T Cell Targets in Multiple Myeloma Patients Treated with Dendritic Cell/Myeloma Fusion Vaccine
(PA-299) A35, a Novel Small Molecule Kinase Inhibitor, Shows High Efficacy in Multiple Myeloma and Overcomes Imids Resistance
(PA-300) Autophagy Disruption via PIKfyve Inhibition Strikingly Upregulates Cholesterol Metabolism in Multiple Myeloma
(PA-301) Enhancing Immunotherapy through Metabolic Modulation in Humanized Multiple Myeloma Mice
(PA-302) Role and Mechanism of Pim-2 Kinase Inhibitors-induced Immunogenic Cell Death in Multiple Myeloma
(PA-303) STAT3 Inhibitors Inducing DNA Damage in Multiple Myeloma Cells and Enhancing the Anti-tumor Effects of NK Cells
(PA-305) Computer-assisted AI to Detect Myeloma Cells
(PA-306) Mezigdomide (MEZI) in Novel Targeted Combinations for Relapsed/refractory Multiple Myeloma (RRMM): Updated Results from the Phase 1/2 CA057-003 Trial
(PA-307) IBERDOMIDE (IBER) TREATMENT (Tx) ENHANCES MANUFACTURED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL EXPANSION AND FUNCTIONALITY AND IS IMMUNOSTIMULATORY IN PATIENTS POST-CAR T CELL THERAPY
(PA-308) Efficacy and Safety of Daratumumab-Based Schemes in Over80_Years Newly Diagnosed Multiple Myeloma(NDMM)
(PA-309) SETD7 Is a Novel Therapeutic Target for Multiple Myeloma Carrying t(11;14)
(PA-310) HUWE1 Inhibition Impacts MYC Expression Leading to Increased DNA Damage in Combination with Bortezomib
(PA-311) Targeting of BIRC3 Sensitises Multiple Myeloma Cells to Proteasome Inhibitors
(PA-312) B7-H3 Is Associated with Worse Outcomes in Newly Diagnosed Myeloma and Can Be Targeted with a Tri-specific Killer Engager
(PA-313) Novel Therapeutic Targets Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) Are Expressed on Malignant Plasma Cells from Patients with Plasma Cell Dyscrasias but Not on Normal Plasma Cells
(PA-314) Exploiting Silver Nanoparticle (AgNP) Induced Proteotoxicity for Multiple Myeloma Treatment
(PA-316) Ex vivo Evaluation of BCL-2 Family Member Dependencies in Multiple Myeloma: Synergistic Combinations and Biomarkers of Sensitivity and Resistance
(PA-318) Precision Medicine in a Patient with Multiple Myeloma Presenting with t(2;11) and CCND1 Overexpression
(PA-319) Preclinical Activity of Pharmacological Inhibitors Targeting KRAS and pan-RAS in Multiple Myeloma
(PA-320) Unc-51 Like Kinase 3 (ULK3) is Essential for Autophagy and Cell Survival in Multiple Myeloma
(PA-321) Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study
(PA-322) eMMpower: A Longitudinal Multi-Center Chart Review Consortium for Multiple Myeloma (MM)
(PA-323) LILRB4 Protects Multiple Myeloma Cells from Ferroptosis to Promote MM Progression
(PA-324) AKR1B1/NAT10 Mediate IL4I1 ac4C Modification to Regulate Tryptophan Metabolism and Promote Multiple Myeloma Proliferation
(PA-325) RNF5-DNAJA1 Axis Dictates Selinexor Sensitivity of Multiple Myeloma
(PA-326) Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation in Multiple Myeloma
(PA-327) Carfilzomib, Pomalidomide, Dexamethasone±daratumumab Delivers Survival Benefit Regardless of Cytogenetic Risk in Early Relapsed Myeloma Patients：a Multi-center, Prospective Real World Study in China
(PA-328) Inhibition of DNA Damage Response Factor DNA-PKcs-mediated H2AX Phosphorylation Enhances Selinexor-induced Anti-multiple Myeloma Effects
(PA-329) A Multi-step Virtual Screening Framework Identifies Novel GPRC5D Inhibitors for Multiple Myeloma Therapy
(PA-523) HDAC and CDK Inhibitor Combinations Synergize in Limiting Myeloma
(PA-532) Targeting JAM-A to Prevent Multiple Myeloma Progression: Novel Peptide Inhibitors Block Proliferation and Offer a New Therapeutic Strategy for High-Risk Disease